Pharmacological proteasome inhibitors and their therapeutic potential

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 8, 2000, Pages 1263-1272

  Dou, Q P ^a   Nam, S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Autoimmune disease; Bone disease; Cancer; Inflammation; Muscle wasting disease; Neurological disease; Parkinson's disease

Indexed keywords

ACLARUBICIN; ALDEHYDE DERIVATIVE; AMSACRINE; BCR ABL PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CALPASTATIN; CASPASE 3; CEP 1612; CISPLATIN; DOXORUBICIN; ETOPOSIDE; INDANONE DERIVATIVE; LACTACYSTIN; METHOTREXATE; MG 101; MITOMYCIN C; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; RAS PROTEIN; TUMOR NECROSIS FACTOR; UBIQUITIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BURKITT LYMPHOMA; CANCER CELL; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN U937; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; ONCOGENE MYC; PATENT; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RAT; REVIEW; SOLID TUMOR; TUMOR XENOGRAFT;

EID: 0033869875     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.8.1263     Document Type: Review

References (52)

1. Ubiquitin, proteasomes and the regulation of intracellular protein degradation
2. The ubiquitin-proteasome proteolytic pathway
3. Proteasome inhibitors as potential novel anticancer agents
4. The role of the ubiquitin-proteasome pathway in apoptosis
5. The ubiquitin-proteasome pathway in cancer
6. The ubiquitin-proteasome pathway and pathogenesis of human diseases
7. The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
8. Human genetic diseases of proteolysis
9. Ubiquitin in homeostasis, development and disease
10. Latacystin, a specific inhibitor of the protesome, induces apotosis in human monoblast U937 cells
11. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells
12. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line
13. Enhancement of cpp32-like activity in the tnf-treated u937 cells by the proteasome inhibitors
14. Apoptosis induction resulting from proteasome inhibition
15. p53-Dependent induction of apoptosis by proteasome inhibitors
16. Novel dipeptidyl proteasome inhibitors overcome bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
17. Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity
18. Eponemycin exerts its antitumor effect through the inhibition of proteasome function
19. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
20. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis
21. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin
22. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit
23. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
24. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
25. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells
26. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance
27. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
28. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs
29. Proteasome inhibitors: A novel class of potent and effective anti-tumor agents
30. The proteasome is involved in angiogenesis
31. PR39, a peptide regulator of angiogenesis
32. Angiogenesis: New targets for the development of anticancer chemotherapies
33. Antiangiogenic therapy in brain tumor models
34. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
35. Mechanistic studies on the inactivation of the proteasome by lactacystin: A central role for clasto-lactacystin beta-lactone
36. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells
37. Structure of 20S proteasome from yeast at 2.4 A resolution
38. Selective proteasome inhibitors: Modulators of antigen presentation?
39. Proteasome inhibitors: Valuable new tools for cell biologists
40. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution
41. Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology
42. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of a',b'-epoxyketon proteasome inhibitors
43. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
44. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G and chymotrypsin by peptide boronic acids
45. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides
46. A new structural class of proteasome inhibitors that prevent NF-kappa B activation
47. Inhibitors of the chymotrypsin-like activity of proteasome based on di-and tri-peptidyl alpha-keto aldehydes (glyoxals)
48. Inhibition of ubiquitin-ATP-dependent proteolysis and ubiquitination by cisplatin
49. Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin
50. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome